Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Precigen

US FDA’s Breakthrough Designation Pace Slows, But Topics Broaden

The 19 breakthrough therapy designations awarded so far this year run the gamut from areas that traditionally have not fared well with BTDs, like cardiovascular and respiratory disease, alongside the traditional cancer and orphan disease tentpoles.

US FDA Performance Tracker Review Pathway

Scrip Asks...What Does 2022 Hold For Biopharma? Part 1: Markets, Competition And Business Strategy

Biopharma industry leaders highlight key concerns and opportunities across production, supply chain and commercial operations. Business transformation is top of mind for many, perhaps unsurprisingly following two years of rapid and mostly successful adaptation to the strictures of the COVID-19 pandemic.

Scrip Asks Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Diversified
  • Pharmaceuticals
  • Pharmaceuticals
    • Chiral Chemistry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Liposomes
    • Nanotechnology, Chips, etc.
    • Pharmacogenetics-Pharmacogenomics
    • Synthesis Technologies, Production Processes
    • Transgenics
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Bioinformatics
      • Molecular Diversity
UsernamePublicRestriction

Register